Doctors Frustrated By Lack Of Guidance On Who Should Get Aduhelm
Broad Label Has No Requirement To Test For Amyloid
Biogen has warned that uptake for its newly approved Alzheimer’s therapy will be slow in the beginning and doctors confirm it will take time to figure which patients can and should be treated.
